Isabella Caroline Chiara Niesner

Isabella Caroline Chiara Niesner


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in Advanced Materials Interfaces
Verified
Journal Article
Open access
NENafise Elahpour
Nafise Elahpour
INIsabella Caroline Chiara Niesner
Isabella Caroline Chiara Niesner
NANora Abdellaoui
Nora Abdellaoui
BHBoris Michael Holzapfel
Boris Michael Holzapfel
LGLukas Gritsch
Lukas Gritsch
JLJonathan Lao
Jonathan Lao
This work focuses on combating bacterial infections in bone tissue using metal elements embedded in bioactive glass. While there is an urgent need for alternative methods with a shrinking number of effective treatment options untouched by antimicrobial resistance, it is crucial to first understand the mechanisms of pathogenesis, persistence, and bacterial resistance in skeletal infection, and then develop effective counterstrategies and innovative alternatives. This review considers the role of antimicrobial metal ions, their mechanism of action, and their incorporation into bioactive glass formulations as these materials can serve as delivery platforms with the least possible complexities. Furthermore, the bacterial infection risk in bone is also examined with specific attention to antibiotic resistance and biofilm formation. This review sheds light on the most promising materials as novel antibacterial agents by presenting a wide range of possible bioactive glass formulations equipped with potential antibacterial ions and in vitro/ in vivo insights, and it also reinforces the importance of continuing studies to develop multi‐faceted antibacterial bioactive glasses.

30 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
NENafise Elahpour
Nafise Elahpour
INIsabella Caroline Chiara Niesner
Isabella Caroline Chiara Niesner
CBCédric Bossard
Cédric Bossard
NANora Abdellaoui
Nora Abdellaoui
Valérie MontouilloutValérie Montouillout
Valérie Montouillout
JLJonathan Lao
Jonathan Lao
A novel organic–inorganic hybrid, based on SiO2-CaO-ZnO bioactive glass (BG) and polycaprolactone (PCL), associating the highly bioactive and versatile bioactive glass with clinically established PCL was examined. The BG–PCL hybrid is obtained by acid-catalyzed silica sol–gel process inside PCL solution either by direct or indirect printing. Apatite-formation tests in simulated body fluid (SBF) confirm the ion release along with the hybrid’s bone-like apatite forming. Kinetics differ significantly between directly and indirectly printed scaffolds, the former requiring longer periods to degrade, while the latter demonstrates faster calcium phosphate (CaP) formation. Remarkably, Zn diffusion and accumulation are observed at the surface within the newly formed active CaP layer. Zn release is found to be dependent on printing method and immersion medium. Investigation of BG at the atomic scale reveals the ambivalent role of Zn, capable of acting both as a network modifier and as a network former linking the BG silicate network. In addition, hMSCs viability assay proves no cytotoxicity of the Zn hybrid. LIVE/DEAD staining demonstrated excellent cell viability and proliferation for over seven weeks. Overall, this hybrid material either non-doped or doped with a metal trace element is a promising candidate to be translated to clinical applications for bone regeneration.

27 November 2024 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
TFTina Frankenbach
Tina Frankenbach
INIsabella Caroline Chiara Niesner
Isabella Caroline Chiara Niesner
PAParveen Ahmed
Parveen Ahmed
HDHans Roland Dürr
Hans Roland Dürr
AKAlexander Klein
Alexander Klein
Susanne Mayer-WagnerSusanne Mayer-Wagner
Susanne Mayer-Wagner
Osteosarcoma is the most common malignant bone tumor, primarily affecting children and young adults. For these young patients, the current treatment options for osteosarcoma impose considerable constraints on daily life with significant morbidity and a low survival rate. Despite ongoing research efforts, the 5-year survival rate of first-diagnosed patients without metastases has not changed in the past four decades. The demand for novel treatments is currently still unmet, in particular for effective second-line therapy. Therefore, there is an urgent need for advanced preclinical models and drug-testing platforms that take into account the complex disease characteristics, the high heterogeneity of the tumour and the interactions with the bone microenvironment. In this review, we provide a comprehensive overview about state-of-the-art tissue-engineered and patient-specific models for osteosarcoma. These sophisticated platforms for advanced therapy trials aim to improve treatment outcomes for future patients by modelling the patient’s disease state in a more accurate and complex way, thus improving the quality of preclinical research studies. Graphical Abstract

31 January 2025 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
INIsabella Caroline Chiara Niesner
Isabella Caroline Chiara Niesner
KBKevin Jon Balbi
Kevin Jon Balbi
BPBenjamin Poskitt
Benjamin Poskitt
CGCarolina Gemma
Carolina Gemma
JLJosep Linares
Josep Linares
DMDavid Allan Moore
David Allan Moore
Kirsten rat sarcoma viral oncogene (KRAS) is a frequently mutated oncogene in lung cancer, now amenable to targeted therapy with allele-specific G12C inhibitors. Non-small cell lung cancer (NSCLC) driver mutations show geographical variability and therefore the KRAS mutation breakdown, co-occurring oncogenic mutation rate and associated PD-L1 expression were studied in a large UK cohort. We interrogated archival clinical next-generation sequencing (NGS) data over 5 years. 3283 NSCLC samples were included, referred from 38 centres over 4 years. Somatic mutation hotspots in cancer-associated genes were analysed using ampliseq/ion-torrent based NGS assays. In a subset of the cohort, PD-L1 scores were also collated. 1118 KRAS variants were detected. Class I mutations occurred most frequently (86.94%), with KRAS G12C, G12V and G12D being most prevalent. Class II (7.96%), III (4.65%) and IV (0.45%) mutations were also detected and mutations in PIK3CA and BRAF were the most frequently observed co-mutations. No significant difference in PD-L1 expression was found between KRAS wild-type and mutant tumours.

11 June 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
FAFranz-Xaver Anzinger
Franz-Xaver Anzinger
INIsabella Caroline Chiara Niesner
Isabella Caroline Chiara Niesner
SPSarah Priem
Sarah Priem
LSLaura Christin Stigler
Laura Christin Stigler
Oliver J. MuenstererOliver J. Muensterer
Oliver J. Muensterer
DWDanielle Wendling-Keim
Danielle Wendling-Keim
Introduction and importance: Gastrointestinal duplication cysts are rare congenital anomalies, usually solitary and most often involving the ileum and esophagus. Multiple non-contiguous duplications are exceptionally uncommon and may mimic more frequent neonatal thoracic or abdominal conditions. Case presentation: We report a term female neonate with a prenatal suspicion of congenital pulmonary airway malformation. Postnatally, she developed respiratory distress due to a large thoracic cyst, which was resected thoracoscopically and confirmed to be an esophageal duplication cyst. Weeks later, recurrent melena and anemia prompted re-evaluation. A Tc-99m pertechnetate scan suggested Meckel’s diverticulum, but laparoscopy revealed a 35 cm tubular ileal duplication with intestinal non-rotation. Resection and Ladd’s procedure were performed, with an uneventful recovery. Histopathology demonstrated gastric metaplasia and pancreatic heterotopia. Clinical discussion: This case highlights the diagnostic difficulty of non-contiguous foregut and midgut duplications presenting metachronously with respiratory distress and gastrointestinal bleeding. Ultrasound remains the preferred first-line modality, with CT, MRI, and Tc-99m pertechnetate scintigraphy used selectively. Complete excision is generally recommended, while suspected residual ectopic gastric mucosa may justify temporary acid suppression and close surveillance when the child is stable and reoperation is not immediately indicated. Conclusions: Gastrointestinal duplications should be considered in neonates with unexplained respiratory or gastrointestinal symptoms, particularly when associated anomalies are present. Multimodal imaging, timely surgery, and structured follow-up are important to prevent recurrent bleeding, obstruction, or other complications.